Impact of a multidisciplinary approach in enteropathic spondyloarthritis patients

Autoimmunity Reviews

Volumn 15, Issue 2, 2016, Pages 184-190

  Conigliaro, Paola ^a   Chimenti, Maria Sole ^a   Ascolani, Marta ^a   Triggianese, Paola ^a   Novelli, Lucia ^a   Onali, Sara ^a   Lolli, Elisabetta ^a   Calabrese, Emma ^a   Petruzziello, Carmelina ^a   Pallone, Francesco ^a   Perricone, Roberto ^a   Biancone, Livia ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Enteropathic spondyloarthritis; Inflammatory bowel disease; Management; Multidisciplinary approach

Indexed keywords

C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE; ARTHRALGIA; ARTHROPATHY; ASEPTIC NECROSIS; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; BEHCET DISEASE; CHONDROCALCINOSIS; CLINICAL ASSESSMENT; CLINICAL FEATURE; COHORT ANALYSIS; DE QUERVAIN TENOSYNOVITIS; DISEASE ACTIVITY; DISEASE DURATION; DUPUYTREN CONTRACTURE; ENTEROPATHIC SPONDYLOARTHRITIS; ERYTHEMA NODOSUM; FEMALE; FIBROMYALGIA; HUMAN; INFLAMMATORY BOWEL DISEASE; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL PAIN; OSTEOARTHRITIS; PANCOLITIS; PATHOGENESIS; PRIMARY SCLEROSING CHOLANGITIS; PROSPECTIVE STUDY; PSORIASIS; REVIEW; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; SMOKING HABIT; SPONDYLARTHRITIS; UVEITIS; COMPLICATION; GENETIC PREDISPOSITION; IMMUNOLOGY; PREVALENCE; RHEUMATIC DISEASE;

GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATORY BOWEL DISEASES; PREVALENCE; RHEUMATIC DISEASES; SPONDYLARTHRITIS;

EID: 84954316739     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2015.11.002     Document Type: Review

References (62)

1. Dougados M., Baeten D. Spondyloarthritis. Lancet 2011, 377:2127-2137.
2. Harper B.E., Reveille J.D. Spondyloarthritis: clinical suspicion, diagnosis, and sports. Curr Sports Med Rep 2009, 8:29-34.
3. Zeidler H., Amor B. The Assessment in Spondyloarthritis International Society (ASAS) classification criteria for peripheral arthritis and for spondyloarthritis in general: the spondyloarthritis concept in progress. Ann Rheum Dis 2011, 70:1-3.
4. Chimenti M.S., Ballanti E., Perricone C., Cipriani P., Giacomelli R., Perricone R. Immunomodulation in psoriatic arthritis: focus on cellular and molecular pathways. Autoimmun Rev 2013, 12:599-606.
5. Breban M., Said-Nahal R., Hugot J.P., Miceli-Richard C. Familial and genetic aspects of spondyloarthropathy. Rheum Dis Clin North Am 2003, 29:575-594.
6. van Hoeven L., Koes B.W., Hazes J.M., Weel A.E. Evaluating the ASAS recommendations for early referral of axial spondyloarthritis in patients with chronic low back pain; is one parameter present sufficient for primary care practice?. Ann Rheum Dis 2015, (pii: annrheumdis-2015-208547). 10.1136/annrheumdis-2015-208547.
7. Poddubnyy D., van Tubergen A., Landewé R., Sieper J., van der Heijde D., Assessment of SpondyloArthritis international Society (ASAS) Development of an ASAS-endorsed recommendation for the early referral of patients with a suspicion of axial spondyloarthritis. Ann Rheum Dis 2015, 74:1483-1487.
8. Orchard T.R., Wordsworth B.P., Jewell D.P. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut 1998, 42:387-391.
9. Peluso R., Di Minno M.N., Iervolino S., Manguso F., Tramontano G., Ambrosino P., et al. Enteropathic spondyloarthritis: from diagnosis to treatment. Clin Dev Immunol 2013, 2013:631408.
10. Podolsky D.K. Inflammatory bowel disease. N Engl J Med 2002, 347:417-429.
11. Xavier R.J., Podolsky D.K. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007, 448:427-434.
12. Salvarani C., Fries W. Clinical features and epidemiology of spondyloarthritides associated with inflammatory bowel disease. World J Gastroenterol 2009, 15:2449-2455.
13. Turkcapar N., Toruner M., Soykan I., Aydintug O.T., Cetinkaya H., Duzgun N., et al. The prevalence of extraintestinal manifestations and HLA association in patients with inflammatory bowel disease. Rheumatol Int 2006, 26:663-668.
14. Dignass A., Lindsay J.O., Sturm A., Windsor A., Colombel J.F., Allez M., et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis: current management. J Crohn's Colitis 2012, 6:991-1030.
15. Dougados M., van der Linden S., Juhlin R., Huitfeldt B., Amor B., Calin A., et al. The European Spondylarthropathy Study Group preliminary criteria for the Clinical and Developmental Immunology classification of spondylarthropathy. Arthritis Rheum 1991, 34:1218-1227.
16. Atzeni F., Defendenti C., Ditto M.C., Batticciotto A., Ventura D., Antivalle M., et al. Rheumatic manifestations in inflammatory bowel disease. Autoimmun Rev 2014, 13:20-23.
17. Khan M. Update on spondyloarthropathies. Ann Intern Med 2002, 136:896-907.
18. Smolen J.S., Breedveld F.C., Burmester G.R., Bykerk V., Dougados M., Emery P., et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis 2014, 73:6-16.
19. Van der Heijde D., Sieper J., Maksymowych W., Dougados M., Burgos-Vargas R., Landewé R., et al. 2010 update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011, 70. (8.5-905).
20. Robinson P.C., Brown M.A. The window of opportunity: a relevant concept for axial spondyloarthritis. Arthritis Res Ther 2014, 16:109.
21. Ward M.M., Deodhar A., Akl E.A., Lui A., Ermann J., Gensler L.S., et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheum 2015, 10.1002/art.39298.
22. Chen J., Lin S., Liu C. Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev 2014, 11. 10.1002/14651858.CD004800.
23. Pontes C., Gratacós J., Torres F., Avendaño C., Sanz J., Vallano A., et al. Evaluation of dose reduction versus standard dosing for maintenance of remission in patients with spondyloarthritis and clinical remission with anti-TNF (REDES-TNF): study protocol for a randomized controlled trial. Trials 2015, 16:370.
24. Fantini M.C., Pallone F., Monteleone G. Common mechanisms in inflammatory bowel disease and spondyloarthropathies. World J Gastroenterol 2009, 15:2472-2478.
25. Nickdel M.B., Conigliaro P., Valesini G., Hutchison S., Benson R., Bundick R.V., et al. Dissecting the contribution of innate and antigen-specific pathways to the breach of self-tolerance in a murine model of arthritis. Ann Rheum Dis 2009, 68:1059-1066.
26. Scrivo R., Conigliaro P., Riccieri V., Di Franco M., Alessandri C., Spadaro A., et al. Distribution of IL-10 family cytokines in serum and synovial fluid of patients with inflammatory arthritis reveals different contribution to systemic and joint inflammation. Clin Exp Immunol 2015, 179:300-308.
27. Yeremenko N., Paramarta J.E., Baeten D. The interleukin-23/interleukin-17 immune axis as a promising new target in the treatment of spondyloarthritis. Curr Opin Rheumatol 2014, 26:361-370.
28. Geremia A., Biancheri P., Allan P., Corazza G.R., Di Sabatino A. Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Rev 2014, 13:3-10.
29. Zhou L., Spolski R., Min R., Shenderov K., Egawa T., Levy D.E., et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 2007, 8:967-974.
30. Ahern P.P., Schiering C., Buonocore S., McGeachy M.J., Cua D.J., Maloy K.J., et al. Interleukin-23 drives intestinal inflammation through direct activity on T cells. Immunity 2010, 33:279-288.
31. Anderson C.A., Boucher G., Lees C.W., Franke A., D'Amato M., Taylor K.D., et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 2011, 43:246-252.
32. Khan M.A., Mathieu A., Sorrentino R., Akkoc N. The pathogenetic role of HLA-B27 and its subtypes. Autoimmun Rev 2007, 6:183-189.
33. Diani M., Altomare G., Reali E. T cell responses in psoriasis and psoriatic arthritis. Autoimmun Rev 2015, 14:286-292.
34. Ciccia F., Bombardieri M., Principato A., Giardina A., Tripodo C., Porcasi R., et al. Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis. Arthritis Rheum 2009, 60:955-965.
35. Hazenberg M.D., Spits H. Human innate lymphoid cells. Blood 2014, 124:700-709.
36. Yazdani R., Sharifi M., Shirvan A.S., Azizi G., Ganjalikhani-Hakemi M. Characteristics of innate lymphoid cells (ILCs) and their role in immunological disorders (an update). Cell Immunol 2015, 26. (pii: S0008-8749(15)30018-6). 10.1016/j.cellimm.2015.09.006.
37. Ciccia F., Accardo-Palumbo A., Rizzo A., Guggino G., Raimondo S., Giardina A., et al. Evidence that autophagy, but not the unfolded protein response, regulates the expression of IL-23 in the gut of patients with ankylosing spondylitis and subclinical gut inflammation. Ann Rheum Dis 2014, 73:1566-1574.
38. Ciccia F., Accardo-Palumbo A., Alessandro R., Rizzo A., Principe S., Peralta S., et al. Interleukin-22 and interleukin-22-producing NKp44+ natural killer cells in subclinical gut inflammation in ankylosing spondylitis. Arthritis Rheum 2012, 64:1869-1878.
39. Aparicio-Domingo P., Romera-Hernandez M., Karrich J.J., Cornelissen F., Papazian N., Lindenbergh-Kortleve D.J., et al. Type 3 innate lymphoid cells maintain intestinal epithelial stem cells after tissue damage. J Exp Med 2015, 212:1783-1791.
40. Ciccia F., Guggino G., Rizzo A., Saieva L., Peralta S., Giardina A., et al. Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients with ankylosing spondylitis. Ann Rheum Dis 2015, 74:1739-1747.
41. Chimenti M.S., Triggianese P., Conigliaro P., Santoro M., Lucchetti R., Perricone R. Self-reported adherence to a home-based exercise program among patients affected by psoriatic arthritis with minimal disease activity. Drug Dev Res 2014, 75:S54-S56.
42. Conigliaro P., Triggianese P., Ippolito F., Lucchetti R., Chimenti M.S., Perricone R. Insights on the role of physical activity in patients with rheumatoid arthritis. Drug Dev Res 2014, 75:57-59.
43. Dignass A., Van Assche G., Lindsay J.O., Lémann M., Söderholm J., European Crohn's and Colitis Organisation (ECCO), et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohn's Colitis 2010, 4:28-62.
44. Satsangi J., Silverberg M.S., Vermeire S., Colombel J.F. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006, 17:749-753.
45. Román A.L., Muñoz F. Comorbidity in inflammatory bowel disease. World J Gastroenterol 2011, 17:2723-2733.
46. Mandl P., Navarro-Compán V., Terslev L., Aegerter P., van der Heijde D., D'Agostino M.A., et al. EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice. Ann Rheum Dis 2015, 74:1327-1339.
47. Weber U., Zhao Z., Rufibach K., Zubler V., Lambert R.G., Chan S.M., et al. Diagnostic utility of candidate definitions for a positive MRI of the spine in patients with axial spondyloarthritis. Arthritis Rheum 2015, 67:924-933.
48. Taylor W., Gladman D., Helliwell P., Marchesoni A., Mease P., Mielants H., et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006, 54:2665-2673.
49. Aletaha D., Neogi T., Silman A.J., Funovits J., Felson D.T., Bingham C.O., et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010, 62:2569-2581.
50. Dalbeth N., Fransen J., Jansen T.L., Neogi T., Schumacher H.R., Taylor W.J. New classification criteria for gout: a framework for progress. Rheumatology (Oxford) 2013, 52:1748-1753.
51. Bennett R.M., Friend R., Marcus D., Bernstein C., Han B.K., Yachoui R., et al. Criteria for the diagnosis of fibromyalgia: validation of the modified 2010 preliminary ACR criteria and the development of alternative criteria. Arthritis Care Res 2014, 66:1364-1373.
52. Zhang W., Doherty M., Peat G., Bierma-Zeinstra M.A., Arden N.K., Bresnihan B., et al. EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis. Ann Rheum Dis 2010, 69:483-489.
53. Braun J., van den Berg R., Baraliakos X., Boehm H., Burgos-Vargas R., Collantes-Estevez E., et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011, 70:896-904.
54. Lukas C., Landewé R., Sieper J., Dougados M., Davis J., Braun J., et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 2009, 68:18-24. Assessment of SpondyloArthritis international Society.
55. Garrett S., Jenkinson T., Kennedy L.G., Whitelock H., Gaisford P., Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994, 21:2286-2291.
56. Calin A., Garrett S., Whitelock H., Kennedy L.G., O'Hea J., Mallorie P., et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994, 21:2281-2285.
57. Daltroy L.H., Larson M.G., Roberts N.W., Liang M.H. A modification of the Health Assessment Questionnaire for the spondyloarthropathies. J Rheumatol 1990, 17:946-950.
58. Colombo E., Latiano A., Palmieri O., Bossa F., Andriulli A., Annese V. Enteropathic spondyloarthropathy: a common genetic background with inflammatory bowel disease?. World J Gastroenterol 2009, 15:2456-2462.
59. Braun J., Sieper J. Ankylosing spondylitis. Lancet 2007, 369:1379-1390.
60. Salvadorini G., Bandinelli F., Delle Sedie A., Riente L., Candelieri A., Generini S., et al. Ankylosing spondylitis: how diagnostic and therapeutic delay have changed over the last six decades. Clin Exp Rheumatol 2012, 30:561-565.
61. Mau W., Zeidler H., Mau R., Majewski A., Freyschmidt J., Stangel W., et al. Clinical features and prognosis of patients with possible ankylosing spondylitis. Results of a 10-year followup. J Rheumatol 1988, 15:1109-1114.
62. Rudwaleit M., van der Heijde D., Khan M.A., Braun J., Sieper J. How to diagnose axial spondyloarthritis early. Ann Rheum Dis 2004, 63:535-543.